These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7052162)

  • 1. Neutrophil adhesiveness during prostacyclin and heparin hemodialysis.
    Spagnuolo PJ; Bass SH; Smith MC; Danviriyasup K; Dunn MJ
    Blood; 1982 Oct; 60(4):924-9. PubMed ID: 7052162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of prostacyclin and heparin on hemodialyses in dogs.
    Gross M; Bush H; McTigue H; Hamburger RJ; Flamenbaum W
    Prostaglandins; 1981 Jun; 21(6):879-88. PubMed ID: 7027320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostacyclin substitution for heparin in long-term hemodialysis.
    Smith MC; Danviriyasup K; Crow JW; Cato AE; Park GD; Hassid A; Dunn MJ
    Am J Med; 1982 Nov; 73(5):669-78. PubMed ID: 6753575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemodialysis using prostacyclin instead of heparin as the sole antithrombotic agent.
    Zusman RM; Rubin RH; Cato AE; Cocchetto DM; Crow JW; Tolkoff-Rubin N
    N Engl J Med; 1981 Apr; 304(16):934-9. PubMed ID: 7010166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissociation of neutrophil aggregation, adhesiveness, and Fc receptor activity.
    Spagnuolo PJ; Fain M; Bass SN
    Am J Hematol; 1987 Nov; 26(3):221-8. PubMed ID: 2445200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet protection and heparin sparing with prostacyclin during regular dialysis therapy.
    Turney JH; Williams LC; Fewell MR; Parsons V; Weston MJ
    Lancet; 1980 Aug; 2(8188):219-22. PubMed ID: 6105392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of prostacyclin on platelets, polymorphonuclear cells, and heterotypic cell aggregation during hemofiltration.
    Kozek-Langenecker SA; Spiss CK; Michalek-Sauberer A; Felfernig M; Zimpfer M
    Crit Care Med; 2003 Mar; 31(3):864-8. PubMed ID: 12626998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostacyclin can replace heparin in haemodialysis in dogs.
    Woods HF; Ash G; Weston MJ; Bunting S; Moncada S; Vane JR
    Lancet; 1978 Nov; 2(8099):1075-7. PubMed ID: 82090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of polymorphonuclear leukocyte adherence by prostacyclin.
    Boxer LA; Allen JM; Schmidt M; Yoder M; Baehner RL
    J Lab Clin Med; 1980 May; 95(5):672-8. PubMed ID: 6245158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostacyclin and thromboxane in chronic uremia: effect of hemodialysis.
    Ylikorkala O; Huttunen K; Järvi J; Viinikka L
    Clin Nephrol; 1982 Aug; 18(2):83-7. PubMed ID: 6754193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostacyclin and heparin during haemodialysis: comparative effects.
    Camici M; Evangelisti L
    Life Support Syst; 1986; 4(3):205-9. PubMed ID: 3537544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicity of plasma from hemodialysis patients treated with heparin or prostacyclin.
    Wessel-Aas T; Berg KJ; Widerøe TE; Wirum E; Nilsen T
    Acta Med Scand; 1984; 216(1):93-9. PubMed ID: 6385637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled study of heparin versus epoprostenol sodium (prostacyclin) as the sole anticoagulant for chronic hemodialysis.
    Caruana RJ; Smith MC; Clyne D; Crow JW; Zinn JM; Diehl JH
    Blood Purif; 1991; 9(5-6):296-304. PubMed ID: 1819317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Lipid behavior during hemodialysis using heparin and prostacyclin].
    Camici M; Evangelisti L
    Minerva Med; 1992 Dec; 83(12):801-4. PubMed ID: 1491759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of heparin and prostacyclin/heparin infusion on platelet aggregation in hemodialyzed patients.
    Kuźniewski M; Sułowicz W; Hanicki Z; Kus J; Nowogrodzka-Zagórska M; Kostka-Trabka E; Bieroń K; Debińska-Kieć A
    Nephron; 1990; 56(2):174-8. PubMed ID: 2243573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epoprostenol (PGI2, prostacyclin) during high-risk hemodialysis: preventing further bleeding complications.
    Swartz RD; Flamenbaum W; Dubrow A; Hall JC; Crow JW; Cato A
    J Clin Pharmacol; 1988 Sep; 28(9):818-25. PubMed ID: 3068260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of the effectiveness of hemodialysis using only heparin or prostacyclin with heparin].
    Kuźniewski M; Sułowicz W
    Przegl Lek; 1990; 47(3):328-31. PubMed ID: 2236625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased platelet sensitivity to prostacyclin during hemodialysis: an effect of platelet/heparin interaction?
    Knudsen F; Kristensen SD; Nielsen AH; Ring T; Stoffersen E
    Clin Nephrol; 1985 Feb; 23(2):107. PubMed ID: 3886225
    [No Abstract]   [Full Text] [Related]  

  • 19. The in vitro bleeding time while using a stable prostacyclin analogue during hemodialysis.
    Maurin N
    Int J Artif Organs; 1988 Jul; 11(4):243-8. PubMed ID: 3045018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutropenia induced by platelet-activating factor (PAF-acether) released from neutrophils: the inhibitory effect of prostacyclin (PGI2).
    Camussi G; Tetta C; Segoloni G; Chiara Deregibus M; Bussolino F
    Agents Actions; 1981 Dec; 11(6-7):550-3. PubMed ID: 7041569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.